Arvinas Inc (ARVN)
Arvinas, Inc. is a clinical-stage biotechnology company listed on the NASDAQ under the symbol ARVN. The company focuses on discovering, developing, and seeking commercialization for therapies designed to degrade disease-causing proteins. Its research is centered on PROTAC targeted protein degraders, which are intended to use the body’s natural protein disposal process to remove selected proteins linked to disease.
Arvinas is advancing several development programs across oncology and neurodegenerative disease. Its pipeline includes ARV-102 for neurodegenerative disorders such as Parkinson’s disease and progressive supranuclear palsy, ARV-806 for cancers with the KRAS G12D mutation, ARV-393 for relapsed or refractory non-Hodgkin lymphoma, ARV-027 for a polyglutamine-expanded androgen receptor target, and vepdegestrant for ER+/HER2- breast cancer. The company also is developing Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766) for metastatic castration-resistant prostate cancer. Arvinas has collaboration agreements with Pfizer, Genentech, F. Hoffmann-La Roche, Carrick Therapeutics, and Bayer. Founded in 2013, the company is based in New Haven, Connecticut.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARVN
|
$9.76
|
49.0% Upside
|
Undervalued
|
$14.46
|
120.8% Upside
|
Bargain
|
Fair
|
0.0%
|
March 1, 2027
|
0.8x
|
1.6x
|
428.9 M
|
-122.1 M
|
1.7%
|
86.9%
|
5.9
|
1,682.1%
|
